Savara Inc. (NASDAQ:SVRA) Receives $10.00 Consensus Price Target from Analysts

Savara Inc. (NASDAQ:SVRA) has received an average rating of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $10.00.

SVRA has been the subject of several research reports. Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th.

Savara Stock Down 2.8%

SVRA opened at $5.30 on Friday. The business’s fifty day moving average is $5.47 and its two-hundred day moving average is $5.44. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -9.14 and a beta of 0.25. Savara has a one year low of $3.34 and a one year high of $7.01.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Analysts anticipate that Savara will post -0.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SVRA. Principal Financial Group Inc. purchased a new position in shares of Savara during the 1st quarter worth $57,000. Sequoia Financial Advisors LLC purchased a new position in Savara during the second quarter worth about $69,000. E Fund Management Co. Ltd. acquired a new stake in Savara in the 2nd quarter worth about $77,000. Inceptionr LLC purchased a new stake in Savara in the 1st quarter valued at about $84,000. Finally, Sanctuary Advisors LLC purchased a new stake in Savara in the 2nd quarter valued at about $87,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company’s primary focus is autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which abnormal accumulation of surfactant in the lungs can impair breathing and oxygen exchange.

Savara’s lead product candidate is molgramostim, an inhaled recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is designed to help restore the function of pulmonary alveolar macrophages, the immune cells responsible for clearing excess surfactant from the lungs.